22,135,656
Vote Records
28,570
Companies
12,092
Funds
3,981
Managers

Home › Companies › ROCKET PHARMACEUTICALS INC. › 2024-2025

ROCKET PHARMACEUTICALS INC. 2024-2025 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and ROCKET PHARMACEUTICALS INC.’s Form 8-K, filed June 18, 2025 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 12Ballot items
  • 220Asset managers, any item
  • 2,413Fund votes
  • June 18, 2025Meeting date

Results at a glance

Meeting of June 18, 2025: 12 items on ROCKET PHARMACEUTICALS INC.’s Form 8-K, filed June 18, 2025: 2 approved · 10 passed (calculated).

Dissent

Significant dissent: 1 director (30.1% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore ROCKET PHARMACEUTICALS INC. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by ROCKET PHARMACEUTICALS INC.

These tallies are ROCKET PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 18, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

ROCKET PHARMACEUTICALS INC. — official shareholder meeting results, meeting held June 18, 2025
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Roderick Wong, M.D. 78,146,900---- 991,94812,227,613 99%Passed (calculated)—
Elect Director: Elisabeth Björk, M.D., Ph.D. 76,976,311---- 2,162,53712,227,613 97%Passed (calculated)—
Elect Director: Carsten Boess 78,224,283---- 914,56512,227,613 99%Passed (calculated)—
Elect Director: Mikael Dolsten, M.D., Ph.D. 76,051,973---- 3,086,87512,227,613 96%Passed (calculated)—
Elect Director: Pedro Granadillo 73,571,818---- 5,567,03012,227,613 93%Passed (calculated)—
Elect Director: Gotham Makker, M.D. 73,798,301---- 5,340,54712,227,613 93%Passed (calculated)—
Elect Director: Fady Malik, M.D., Ph.D. 78,249,290---- 889,55812,227,613 99%Passed (calculated)—
Elect Director: Piratip Pratumsuwan 78,595,512---- 543,33612,227,613 99.3%Passed (calculated)—
Elect Director: Gaurav Shah, M.D. 78,411,712---- 727,13612,227,613 99.1%Passed (calculated)—
Elect Director: David P. Southwell 55,352,568---- 23,786,28012,227,613 70%Passed (calculated)—
2. Ratification of Appointment of Independent Registered Accounting Firm 90,696,301141,826528,334 ---- 99.8%Approved—
3. Non-Binding Advisory Vote on the Compensation of the Company's Named Executive Officers 77,186,2211,437,605515,022 --12,227,613 98%Approved—

Source: ROCKET PHARMACEUTICALS INC., Form 8-K, filed with the SEC on June 18, 2025 — read the filing on EDGAR.

How asset managers voted at the ROCKET PHARMACEUTICALS INC. 2024-2025 meeting

220 asset managers disclosed a vote on at least one ROCKET PHARMACEUTICALS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: David P. Southwell

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

70% Majority: yes · of votes cast

FOR 70%WITHHELD
FOR: 55,352,568WITHHELD: 23,786,280

Prior year: 99.6% for (June 13, 2024 meeting) ▼ 29.6 pts

Details: description as filed, official tally, votes by 63 asset managers

Description as filed by funds: Election of the ten directors named in the proxy statement to hold office until the annual meeting of stockholders in 2026, or until their respective successors have been duly elected and qualified or until their earlier death, resignation or removal: David P. Southwell

ROCKET PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: David P. Southwell”): 55,352,568 for, 23,786,280 withheld, per its Form 8-K filed June 18, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 70% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 63 asset managers below reported 17,043,543 for, 9,698,261 withheld, 0 abstained.

FORWITHHOLD
FOR: 17,043,543ABSTAIN: 0WITHHOLD: 9,698,261
Largest asset managers voting on “Election of the ten directors named in the proxy statement to hold office until the annual meeting of stockhol” at ROCKET PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard10,905,5470 0654For
BlackRock00 02,621,298Withhold
State Street5,3340 01,915,512Withhold
Fidelity1,785,1040 034,462For
Federated Hermes1,363,5560 00For
HARBOR FUNDS00 01,232,835Withhold
T. Rowe Price1,186,6720 00For
Putnam00 01,015,789Withhold
MUTUAL FUND SERIES TRUST770,6910 00For
Charles Schwab00 0686,480Withhold
TIAA00 0392,835Withhold
Hartford343,2300 00For
Invesco00 0322,438Withhold
Equitable16,9560 0194,884Mixed
Goldman Sachs00 0194,102Withhold
Harbor Funds II182,4820 00For
Global X149,6260 00For
John Hancock118,4550 025,661Mixed
QUANTITATIVE MASTER SERIES LLC00 0131,134Withhold
Prudential/PGIM00 0119,188Withhold
Mercer Funds00 0110,161Withhold
Direxion Shares ETF Trust00 092,025Withhold
Morgan Stanley00 076,420Withhold
MassMutual59,2390 00For
Lincoln Financial00 058,701Withhold

Showing the 25 largest of 63 asset managers. All 63 are in the interactive database (link above).

Elect Director: Carsten Boess

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%
FOR: 78,224,283WITHHELD: 914,565

Prior year: 99.2% for (June 13, 2024 meeting) ▼ 0.4 pts

Details: description as filed, official tally, votes by 63 asset managers

Description as filed by funds: Election of the ten directors named in the proxy statement to hold office until the annual meeting of stockholders in 2026, or until their respective successors have been duly elected and qualified or until their earlier death, resignation or removal: Carsten Boess

ROCKET PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Carsten Boess”): 78,224,283 for, 914,565 withheld, per its Form 8-K filed June 18, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 99% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 63 asset managers below reported 26,741,661 for, 143 withheld, 0 abstained.

FOR
FOR: 26,741,661ABSTAIN: 0WITHHOLD: 143
Largest asset managers voting on “Election of the ten directors named in the proxy statement to hold office until the annual meeting of stockhol” at ROCKET PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard10,906,2010 00For
BlackRock2,621,2980 00For
State Street1,920,8460 00For
Fidelity1,819,5660 00For
Federated Hermes1,363,5560 00For
HARBOR FUNDS1,232,8350 00For
T. Rowe Price1,186,6720 00For
Putnam1,015,7890 00For
MUTUAL FUND SERIES TRUST770,6910 00For
Charles Schwab686,4800 00For
TIAA392,8350 00For
Hartford343,2300 00For
Invesco322,4380 00For
Equitable211,8400 00For
Goldman Sachs194,1020 00For
Harbor Funds II182,4820 00For
Global X149,6260 00For
John Hancock144,1160 00For
QUANTITATIVE MASTER SERIES LLC131,1340 00For
Prudential/PGIM119,1880 00For
Mercer Funds110,1610 00For
Direxion Shares ETF Trust92,0250 00For
Morgan Stanley76,4200 00For
MassMutual59,2390 00For
Lincoln Financial58,7010 00For

Showing the 25 largest of 63 asset managers. All 63 are in the interactive database (link above).

Elect Director: Fady Malik, M.D., Ph.D.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%
FOR: 78,249,290WITHHELD: 889,558

Prior year: 99.7% for (June 13, 2024 meeting) ▼ 0.8 pts

Details: description as filed, official tally, votes by 63 asset managers

Description as filed by funds: Election of the ten directors named in the proxy statement to hold office until the annual meeting of stockholders in 2026, or until their respective successors have been duly elected and qualified or until their earlier death, resignation or removal: Fady Malik, M.D., Ph.D.

ROCKET PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Fady Malik, M.D., Ph.D.”): 78,249,290 for, 889,558 withheld, per its Form 8-K filed June 18, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 99% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 63 asset managers below reported 26,741,804 for, 0 abstained.

FOR
FOR: 26,741,804ABSTAIN: 0
Largest asset managers voting on “Election of the ten directors named in the proxy statement to hold office until the annual meeting of stockhol” at ROCKET PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard10,906,2010 00For
BlackRock2,621,2980 00For
State Street1,920,8460 00For
Fidelity1,819,5660 00For
Federated Hermes1,363,5560 00For
HARBOR FUNDS1,232,8350 00For
T. Rowe Price1,186,6720 00For
Putnam1,015,7890 00For
MUTUAL FUND SERIES TRUST770,6910 00For
Charles Schwab686,4800 00For
TIAA392,8350 00For
Hartford343,2300 00For
Invesco322,4380 00For
Equitable211,8400 00For
Goldman Sachs194,1020 00For
Harbor Funds II182,4820 00For
Global X149,6260 00For
John Hancock144,1160 00For
QUANTITATIVE MASTER SERIES LLC131,1340 00For
Prudential/PGIM119,1880 00For
Mercer Funds110,1610 00For
Direxion Shares ETF Trust92,0250 00For
Morgan Stanley76,4200 00For
MassMutual59,2390 00For
Lincoln Financial58,7010 00For

Showing the 25 largest of 63 asset managers. All 63 are in the interactive database (link above).

Elect Director: Gotham Makker, M.D.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

93% Majority: yes · of votes cast

FOR 93%
FOR: 73,798,301WITHHELD: 5,340,547

Prior year: 99.4% for (June 13, 2024 meeting) ▼ 6.2 pts

Details: description as filed, official tally, votes by 63 asset managers

Description as filed by funds: Election of the ten directors named in the proxy statement to hold office until the annual meeting of stockholders in 2026, or until their respective successors have been duly elected and qualified or until their earlier death, resignation or removal: Gotham Makker, M.D.

ROCKET PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Gotham Makker, M.D.”): 73,798,301 for, 5,340,547 withheld, per its Form 8-K filed June 18, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 93% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 63 asset managers below reported 24,513,901 for, 2,227,903 withheld, 0 abstained.

FOR
FOR: 24,513,901ABSTAIN: 0WITHHOLD: 2,227,903
Largest asset managers voting on “Election of the ten directors named in the proxy statement to hold office until the annual meeting of stockhol” at ROCKET PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard10,905,5470 0654For
BlackRock2,621,2980 00For
State Street1,920,8460 00For
Fidelity1,819,5660 00For
Federated Hermes00 01,363,556Withhold
HARBOR FUNDS1,232,8350 00For
T. Rowe Price1,186,6720 00For
Putnam1,015,7890 00For
MUTUAL FUND SERIES TRUST770,6910 00For
Charles Schwab00 0686,480Withhold
TIAA392,8350 00For
Hartford343,2300 00For
Invesco322,4380 00For
Equitable211,8400 00For
Goldman Sachs194,1020 00For
Harbor Funds II182,4820 00For
Global X00 0149,626Withhold
John Hancock144,1160 00For
QUANTITATIVE MASTER SERIES LLC131,1340 00For
Prudential/PGIM119,1880 00For
Mercer Funds110,1610 00For
Direxion Shares ETF Trust92,0250 00For
Morgan Stanley76,4200 00For
MassMutual59,2390 00For
Lincoln Financial58,7010 00For

Showing the 25 largest of 63 asset managers. All 63 are in the interactive database (link above).

Elect Director: Gaurav Shah, M.D.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

99.1% Majority: yes · of votes cast

FOR 99.1%
FOR: 78,411,712WITHHELD: 727,136

Prior year: 99.5% for (June 13, 2024 meeting) ▼ 0.4 pts

Details: description as filed, official tally, votes by 63 asset managers

Description as filed by funds: Election of the ten directors named in the proxy statement to hold office until the annual meeting of stockholders in 2026, or until their respective successors have been duly elected and qualified or until their earlier death, resignation or removal: Gaurav Shah, M.D.

ROCKET PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Gaurav Shah, M.D.”): 78,411,712 for, 727,136 withheld, per its Form 8-K filed June 18, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 99.1% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 63 asset managers below reported 26,741,804 for, 0 abstained.

FOR
FOR: 26,741,804ABSTAIN: 0
Largest asset managers voting on “Election of the ten directors named in the proxy statement to hold office until the annual meeting of stockhol” at ROCKET PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard10,906,2010 00For
BlackRock2,621,2980 00For
State Street1,920,8460 00For
Fidelity1,819,5660 00For
Federated Hermes1,363,5560 00For
HARBOR FUNDS1,232,8350 00For
T. Rowe Price1,186,6720 00For
Putnam1,015,7890 00For
MUTUAL FUND SERIES TRUST770,6910 00For
Charles Schwab686,4800 00For
TIAA392,8350 00For
Hartford343,2300 00For
Invesco322,4380 00For
Equitable211,8400 00For
Goldman Sachs194,1020 00For
Harbor Funds II182,4820 00For
Global X149,6260 00For
John Hancock144,1160 00For
QUANTITATIVE MASTER SERIES LLC131,1340 00For
Prudential/PGIM119,1880 00For
Mercer Funds110,1610 00For
Direxion Shares ETF Trust92,0250 00For
Morgan Stanley76,4200 00For
MassMutual59,2390 00For
Lincoln Financial58,7010 00For

Showing the 25 largest of 63 asset managers. All 63 are in the interactive database (link above).

Elect Director: Mikael Dolsten, M.D., Ph.D.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%
FOR: 76,051,973WITHHELD: 3,086,875
Details: description as filed, official tally, votes by 63 asset managers

Description as filed by funds: Election of the ten directors named in the proxy statement to hold office until the annual meeting of stockholders in 2026, or until their respective successors have been duly elected and qualified or until their earlier death, resignation or removal: Mikael Dolsten, M.D., Ph.D.

ROCKET PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Mikael Dolsten, M.D., Ph.D.”): 76,051,973 for, 3,086,875 withheld, per its Form 8-K filed June 18, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 96% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 63 asset managers below reported 24,362,459 for, 2,379,345 withheld, 0 abstained.

FOR
FOR: 24,362,459ABSTAIN: 0WITHHOLD: 2,379,345
Largest asset managers voting on “Election of the ten directors named in the proxy statement to hold office until the annual meeting of stockhol” at ROCKET PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard10,906,2010 00For
BlackRock2,621,2980 00For
State Street1,920,8460 00For
Fidelity1,819,5660 00For
Federated Hermes00 01,363,556Withhold
HARBOR FUNDS1,232,8350 00For
T. Rowe Price1,186,6720 00For
Putnam00 01,015,789Withhold
MUTUAL FUND SERIES TRUST770,6910 00For
Charles Schwab686,4800 00For
TIAA392,8350 00For
Hartford343,2300 00For
Invesco322,4380 00For
Equitable211,8400 00For
Goldman Sachs194,1020 00For
Harbor Funds II182,4820 00For
Global X149,6260 00For
John Hancock144,1160 00For
QUANTITATIVE MASTER SERIES LLC131,1340 00For
Prudential/PGIM119,1880 00For
Mercer Funds110,1610 00For
Direxion Shares ETF Trust92,0250 00For
Morgan Stanley76,4200 00For
MassMutual59,2390 00For
Lincoln Financial58,7010 00For

Showing the 25 largest of 63 asset managers. All 63 are in the interactive database (link above).

Elect Director: Pedro Granadillo

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

93% Majority: yes · of votes cast

FOR 93%
FOR: 73,571,818WITHHELD: 5,567,030

Prior year: 71.5% for (June 13, 2024 meeting) ▲ 21.5 pts

Details: description as filed, official tally, votes by 63 asset managers

Description as filed by funds: Election of the ten directors named in the proxy statement to hold office until the annual meeting of stockholders in 2026, or until their respective successors have been duly elected and qualified or until their earlier death, resignation or removal: Pedro Granadillo

ROCKET PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Pedro Granadillo”): 73,571,818 for, 5,567,030 withheld, per its Form 8-K filed June 18, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 93% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 63 asset managers below reported 25,878,915 for, 862,889 withheld, 0 abstained.

FOR
FOR: 25,878,915ABSTAIN: 0WITHHOLD: 862,889
Largest asset managers voting on “Election of the ten directors named in the proxy statement to hold office until the annual meeting of stockhol” at ROCKET PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard10,905,5470 0654For
BlackRock2,621,2980 00For
State Street1,920,8460 00For
Fidelity1,819,5660 00For
Federated Hermes1,363,5560 00For
HARBOR FUNDS1,232,8350 00For
T. Rowe Price1,186,6720 00For
Putnam1,015,7890 00For
MUTUAL FUND SERIES TRUST770,6910 00For
Charles Schwab686,4800 00For
TIAA00 0392,835Withhold
Hartford343,2300 00For
Invesco322,4380 00For
Equitable138,0800 073,760Mixed
Goldman Sachs123,5000 070,602Mixed
Harbor Funds II182,4820 00For
Global X00 0149,626Withhold
John Hancock144,1160 00For
QUANTITATIVE MASTER SERIES LLC131,1340 00For
Prudential/PGIM8,0700 0111,118Mixed
Mercer Funds110,1610 00For
Direxion Shares ETF Trust92,0250 00For
Morgan Stanley76,4200 00For
MassMutual59,2390 00For
Lincoln Financial58,7010 00For

Showing the 25 largest of 63 asset managers. All 63 are in the interactive database (link above).

Elect Director: Piratip Pratumsuwan

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

99.3% Majority: yes · of votes cast

FOR 99.3%
FOR: 78,595,512WITHHELD: 543,336
Details: description as filed, official tally, votes by 63 asset managers

Description as filed by funds: Election of the ten directors named in the proxy statement to hold office until the annual meeting of stockholders in 2026, or until their respective successors have been duly elected and qualified or until their earlier death, resignation or removal: Piratip Pratumsuwan

ROCKET PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Piratip Pratumsuwan”): 78,595,512 for, 543,336 withheld, per its Form 8-K filed June 18, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 99.3% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 63 asset managers below reported 26,741,804 for, 0 abstained.

FOR
FOR: 26,741,804ABSTAIN: 0
Largest asset managers voting on “Election of the ten directors named in the proxy statement to hold office until the annual meeting of stockhol” at ROCKET PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard10,906,2010 00For
BlackRock2,621,2980 00For
State Street1,920,8460 00For
Fidelity1,819,5660 00For
Federated Hermes1,363,5560 00For
HARBOR FUNDS1,232,8350 00For
T. Rowe Price1,186,6720 00For
Putnam1,015,7890 00For
MUTUAL FUND SERIES TRUST770,6910 00For
Charles Schwab686,4800 00For
TIAA392,8350 00For
Hartford343,2300 00For
Invesco322,4380 00For
Equitable211,8400 00For
Goldman Sachs194,1020 00For
Harbor Funds II182,4820 00For
Global X149,6260 00For
John Hancock144,1160 00For
QUANTITATIVE MASTER SERIES LLC131,1340 00For
Prudential/PGIM119,1880 00For
Mercer Funds110,1610 00For
Direxion Shares ETF Trust92,0250 00For
Morgan Stanley76,4200 00For
MassMutual59,2390 00For
Lincoln Financial58,7010 00For

Showing the 25 largest of 63 asset managers. All 63 are in the interactive database (link above).

Elect Director: Roderick Wong, M.D.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 2 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%
FOR: 78,146,900WITHHELD: 991,948

Prior year: 99.1% for (June 13, 2024 meeting) ▼ 0.3 pts

Details: description as filed, official tally, votes by 63 asset managers

Description as filed by funds: Election of the ten directors named in the proxy statement to hold office until the annual meeting of stockholders in 2026, or until their respective successors have been duly elected and qualified or until their earlier death, resignation or removal: Roderick Wong, M.D.

ROCKET PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Roderick Wong, M.D.”): 78,146,900 for, 991,948 withheld, per its Form 8-K filed June 18, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 99% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 63 asset managers below reported 26,713,960 for, 27,844 withheld, 0 abstained.

FOR
FOR: 26,713,960ABSTAIN: 0WITHHOLD: 27,844
Largest asset managers voting on “Election of the ten directors named in the proxy statement to hold office until the annual meeting of stockhol” at ROCKET PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard10,905,5470 0654For
BlackRock2,621,2980 00For
State Street1,920,8100 036For
Fidelity1,819,5660 00For
Federated Hermes1,363,5560 00For
HARBOR FUNDS1,232,8350 00For
T. Rowe Price1,186,6720 00For
Putnam1,015,7890 00For
MUTUAL FUND SERIES TRUST770,6910 00For
Charles Schwab686,4800 00For
TIAA392,8350 00For
Hartford343,2300 00For
Invesco322,4380 00For
Equitable211,8400 00For
Goldman Sachs194,1020 00For
Harbor Funds II182,4820 00For
Global X149,6260 00For
John Hancock144,1160 00For
QUANTITATIVE MASTER SERIES LLC131,1340 00For
Prudential/PGIM119,1880 00For
Mercer Funds110,1610 00For
Direxion Shares ETF Trust92,0250 00For
Morgan Stanley76,4200 00For
MassMutual59,2390 00For
Lincoln Financial58,7010 00For

Showing the 25 largest of 63 asset managers. All 63 are in the interactive database (link above).

Elect Director: Elisabeth Björk, M.D., Ph.D.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 4 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%
FOR: 76,976,311WITHHELD: 2,162,537

Prior year: 94.0% for (June 13, 2024 meeting) ▲ 3.3 pts

Details: description as filed, official tally, votes by 60 asset managers

Description as filed by funds: Election of the ten directors named in the proxy statement to hold office until the annual meeting of stockholders in 2026, or until their respective successors have been duly elected and qualified or until their earlier death, resignation or removal: Elisabeth Bjork, M.D., Ph.D.

ROCKET PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Elisabeth Björk, M.D., Ph.D.”): 76,976,311 for, 2,162,537 withheld, per its Form 8-K filed June 18, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 97% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 60 asset managers below reported 24,930,967 for, 1,035,146 withheld, 0 abstained.

FOR
FOR: 24,930,967ABSTAIN: 0WITHHOLD: 1,035,146
Largest asset managers voting on “Election of the ten directors named in the proxy statement to hold office until the annual meeting of stockhol” at ROCKET PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard10,906,2010 00For
BlackRock2,621,2980 00For
State Street1,920,8460 00For
Fidelity1,819,5660 00For
Federated Hermes1,363,5560 00For
HARBOR FUNDS1,232,8350 00For
T. Rowe Price1,186,6720 00For
Putnam00 01,015,789Withhold
Charles Schwab686,4800 00For
TIAA392,8350 00For
Hartford343,2300 00For
Invesco322,4380 00For
Equitable211,8400 00For
Goldman Sachs194,1020 00For
Harbor Funds II182,4820 00For
Global X149,6260 00For
John Hancock144,1160 00For
QUANTITATIVE MASTER SERIES LLC131,1340 00For
Prudential/PGIM119,1880 00For
Mercer Funds110,1610 00For
Direxion Shares ETF Trust92,0250 00For
Morgan Stanley76,4200 00For
MassMutual59,2390 00For
Lincoln Financial58,7010 00For
Delaware/Macquarie58,0000 00For

Showing the 25 largest of 60 asset managers. All 60 are in the interactive database (link above).

Non-Binding Advisory Vote on the Compensation of the Company's Named Executive Officers

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 12 wordings of this item as funds reported it.

98% Approved · of votes cast

FOR 98%
FOR: 77,186,221AGAINST: 1,437,605

Prior year: 98.4% for (June 13, 2024 meeting) ▼ 0.2 pts

Details: description as filed, official tally, votes by 220 asset managers

Description as filed by funds: Consider and act upon a non-binding, advisory vote on the compensation of our named executive officers;

ROCKET PHARMACEUTICALS INC.’s own tally for this item (“3. Non-Binding Advisory Vote on the Compensation of the Company's Named Executive Officers”): 77,186,221 for, 1,437,605 against — passed, per its Form 8-K filed June 18, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal Three - Non-Binding Advisory Vote on the Compensation of the Company's Named Executive Officers The Company's stockholders approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers, as disclosed in the 2025 Proxy Statement pursuant to Section 14…”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 62 asset managers voting on “Consider and act upon a non-binding, advisory vote on the compensation of our named executive officers;” at ROCKET PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard10,905,547654 00For
BlackRock2,621,2980 00For
State Street1,920,8460 00For
Fidelity1,819,5660 00For
Federated Hermes1,363,5560 00For
HARBOR FUNDS1,232,8350 00For
T. Rowe Price1,186,6720 00For
Putnam1,015,7890 00For
MUTUAL FUND SERIES TRUST770,6910 00For
Charles Schwab686,4800 00For
TIAA392,8350 00For
Hartford343,2300 00For
Invesco322,4380 00For
Equitable211,8400 00For
Goldman Sachs194,1020 00For
Harbor Funds II182,4820 00For
Global X149,6260 00For
John Hancock144,1160 00For
QUANTITATIVE MASTER SERIES LLC131,1340 00For
Prudential/PGIM119,1880 00For
Mercer Funds110,1610 00For
Direxion Shares ETF Trust92,0250 00For
Morgan Stanley76,4200 00For
MassMutual59,2390 00For
Lincoln Financial58,7010 00For

Fund voting reports, all 62 managers: 26,741,007 for, 797 against, 0 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 175 asset managers voting on “Consider and act upon a non-binding, advisory vote on the compensation of our named executive officers;” at ROCKET PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
RTW INVESTMENTS, LP16,734,2170 00For
Wellington7,225,9200 00For
MAVERICK CAPITAL LTD4,869,7250 00For
SUVRETTA CAPITAL MANAGEMENT, LLC4,094,3870 00For
WESTFIELD CAPITAL MANAGEMENT CO LP3,531,8880 00For
State Street3,343,9070 00For
BlackRock3,175,9380 00For
GEODE CAPITAL MANAGEMENT, LLC2,007,2290 00For
T. Rowe Price1,621,5210 00For
Federated Hermes1,399,0670 00For
PICTET ASSET MANAGEMENT SA1,191,5680 00For
MPM BioImpact LLC1,146,6600 00For
Novo Holdings A/S1,100,0000 00For
PARAMETRIC PORTFOLIO ASSOCIATES LLC1,049,2020 00For
Putnam1,015,7890 00For
COMERICA BANK823,9080 00For
Charles Schwab689,7240 00For
Nantahala Capital Management, LLC629,7490 00For
Siren, L.L.C.591,2630 00For
JPMorgan562,8230 00For
Citadel500,0330 00For
Northern Trust415,6830 00For
Nuveen394,6630 00For
SYNOVUS FINANCIAL CORP389,6060 00For
M28 Capital Management LP385,6800 00For

Institutional-manager reports, all 175 managers: 63,447,548 for, 696,821 against, 201,916 abstained, 77,356 not voted. Showing the 25 largest; every one is in the interactive database (link above).

Ratification of Appointment of Independent Registered Accounting Firm

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 2 wordings of this item as funds reported it.

99.8% Approved · of votes cast

FOR 99.8%
FOR: 90,696,301AGAINST: 141,826

Prior year: 99.9% for (June 13, 2024 meeting) unchanged

Details: description as filed, official tally, votes by 63 asset managers

Description as filed by funds: Ratification of the appointment of EisnerAmper LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025;

ROCKET PHARMACEUTICALS INC.’s own tally for this item (“2. Ratification of Appointment of Independent Registered Accounting Firm”): 90,696,301 for, 141,826 against — passed, per its Form 8-K filed June 18, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal Two - Ratification of Appointment of Independent Registered Accounting Firm The Company's stockholders ratified the appointment of EisnerAmper LLP as the Company's independent registered accounting firm for the fiscal year ending December 31, 2025 by the following votes:”
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 63 asset managers below reported 26,741,694 for, 110 against, 0 abstained.

FOR
FOR: 26,741,694AGAINST: 110ABSTAIN: 0
Largest asset managers voting on “Ratification of the appointment of EisnerAmper LLP as the Company's independent registered public accounting f” at ROCKET PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard10,906,2010 00For
BlackRock2,621,2980 00For
State Street1,920,736110 00For
Fidelity1,819,5660 00For
Federated Hermes1,363,5560 00For
HARBOR FUNDS1,232,8350 00For
T. Rowe Price1,186,6720 00For
Putnam1,015,7890 00For
MUTUAL FUND SERIES TRUST770,6910 00For
Charles Schwab686,4800 00For
TIAA392,8350 00For
Hartford343,2300 00For
Invesco322,4380 00For
Equitable211,8400 00For
Goldman Sachs194,1020 00For
Harbor Funds II182,4820 00For
Global X149,6260 00For
John Hancock144,1160 00For
QUANTITATIVE MASTER SERIES LLC131,1340 00For
Prudential/PGIM119,1880 00For
Mercer Funds110,1610 00For
Direxion Shares ETF Trust92,0250 00For
Morgan Stanley76,4200 00For
MassMutual59,2390 00For
Lincoln Financial58,7010 00For

Showing the 25 largest of 63 asset managers. All 63 are in the interactive database (link above).

Largest ROCKET PHARMACEUTICALS INC. shareholders voting in 2024-2025

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 106,753,886 shares outstanding at the time of that meeting.

Fund voting reports: top ROCKET PHARMACEUTICALS INC. shareholders by shares voted on “Consider and act upon a non-binding, advisory vote on the compensation of our named executive…”, 2024-2025
#Asset manager % of shares outstanding
1Vanguard 10.22%
2BlackRock 2.46%
3State Street 1.80%
4Fidelity 1.70%
5Federated Hermes 1.28%
6HARBOR FUNDS 1.15%
7T. Rowe Price 1.11%
8Putnam 0.95%
9MUTUAL FUND SERIES TRUST 0.72%
10Charles Schwab 0.64%
Institutional-manager reports: top ROCKET PHARMACEUTICALS INC. shareholders by shares voted on “Consider and act upon a non-binding, advisory vote on the compensation of our named executive…”, 2024-2025
#Asset manager % of shares outstanding
1RTW INVESTMENTS, LP 15.68%
2Wellington 6.77%
3MAVERICK CAPITAL LTD 4.56%
4SUVRETTA CAPITAL MANAGEMENT, LLC 3.84%
5WESTFIELD CAPITAL MANAGEMENT CO LP 3.31%
6State Street 3.13%
7BlackRock 2.98%
8GEODE CAPITAL MANAGEMENT, LLC 1.88%
9T. Rowe Price 1.52%
10Federated Hermes 1.31%

Reported ROCKET PHARMACEUTICALS INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

ROCKET PHARMACEUTICALS INC. holdings and ownership disclosed for the 2024-2025 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
RTW Investments, LP18,188,457 17.04%Proxy statement (DEF 14A), proxy filed April 30, 2025
Wellington Management12,626,491 11.83%Form 13F, quarter ended March 31, 2025
BlackRock7,274,234 6.81%Form 13F, quarter ended March 31, 2025
Vanguard Group6,617,784 6.20%Form 13F, quarter ended March 31, 2025
Maverick Capital, Ltd.5,547,175 5.20%Proxy statement (DEF 14A), proxy filed April 30, 2025
State Street3,705,461 3.47%Form 13F, quarter ended March 31, 2025
Gaurav Shah, M.D.3,209,364 3.01%Proxy statement (DEF 14A), proxy filed April 30, 2025
T. Rowe Price3,043,682 2.85%Form 13F, quarter ended March 31, 2025
Morgan Stanley2,641,892 2.47%Form 13F, quarter ended March 31, 2025
Geode Capital1,994,044 1.87%Form 13F, quarter ended March 31, 2025

Percentages above are of 106,753,886 shares outstanding, as reported by ROCKET PHARMACEUTICALS INC. on its Form 10-Q dated March 31, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At ROCKET PHARMACEUTICALS INC.'s shareholder meeting held June 18, 2025, in the 2024-2025 proxy season, 220 asset managers reported votes on at least one of its 12 ballot items in their SEC Form N-PX filings, covering 2,413 separate fund positions. On the most widely held item on that ballot — Consider and act upon a non-binding, advisory vote on the compensation of our named executive… — ROCKET PHARMACEUTICALS INC.'s filing reports the proposal as approved, with 98% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: ROCKET PHARMACEUTICALS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 18, 2025.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from ROCKET PHARMACEUTICALS INC.’s 10-Q dated March 31, 2025. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

ROCKET PHARMACEUTICALS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.

Cite this page

Proxy Votes Now, “ROCKET PHARMACEUTICALS (RCKT) 2025 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/rocket-pharmaceuticals-inc/2025 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.